Canada markets open in 6 hours 15 minutes

Kura Oncology, Inc. (KURA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.00+0.25 (+1.33%)
At close: 04:00PM EDT
19.00 0.00 (0.00%)
After hours: 04:20PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close18.75
Open18.26
Bid18.98 x 200
Ask19.05 x 200
Day's Range17.96 - 19.22
52 Week Range7.41 - 24.17
Volume827,642
Avg. Volume1,144,456
Market Cap1.447B
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-2.08
Earnings DateMay 02, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.25
  • GlobeNewswire

    Kura Oncology to Report First Quarter 2024 Financial Results

    SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report first quarter 2024 financial results after the close of U.S. financial markets on Thursday, May 2, 2024. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a co

  • GlobeNewswire

    Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

    – Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its investigational drug, ziftomenib,

  • GlobeNewswire

    Kura Oncology to Participate in Stifel Targeted Oncology Forum

    SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Stifel 2024 Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 11:30 a.m. ET / 8:30 a.m. PT on April 17, 2024. A live audio webcast of the fireside chat w